Bladder Cancer

As leaders in the development of the most sophisticated treatments for people with bladder cancer, we have one of the largest bladder cancer clinical trials program in the United States. Our doctors are leading innovative clinical trials to treat noninvasive bladder cancer—the most common type. Our team of urologic surgeons, medical oncologists, radiation oncologists, imaging specialists, and urologic pathologists collaborates to diagnose and treat people who have bladder cancer.

Our research studies give you access to the newest approaches to care, including the latest diagnostic imaging techniques, such as PET/MRI scans, and advanced treatments, including immunotherapy, and blue light cystoscopy to detect and remove early stage bladder cancer. We are also at the forefront of surgical treatment of bladder cancer, including robotic-assisted surgery, bladder reconstructive surgery, and nerve-sparing techniques that help preserve urinary and sexual function.

Clinical Trials and Research Studies

Phase 3

A Phase 3 Randomized Open-Label Three Arm Study of PF-06801591 in Combination with BCG (Induction With or Without Maintenance) Versus BCG (Induction and Maintenance) in Participants with HR BCG-Na ve NMIBC (B8011006)

Learn More

Phase 3

A Phase 3 Randomized Comparator-controlled Study of the Efficacy and Safety of Pembro in Comb. with BCG in Participants with HR Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction

Learn More

Phase 3

A Phase 3 Randomized Double-blind Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with MIBC (KEYNOTE-992)

Learn More

Phase 1

A Phase 1 First-in Human Multi-Center Open Label Dose-Escalation Study to Determine the Safety Tolerability Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors (AbbVie M19-345)

Learn More